North Staffordshire Joint Formulary Formulary


	North Staffordshire Joint Formulary North Staffordshire Clinical Commissioning Group Stoke-on-Trent Clinical Commissioning Group

Search

Formulary Chapter 2: Cardiovascular system - Full Chapter

02.06.02

Calcium-channel blockers

Amlodipine

Formulary

Amlodipine 5mg Tablet
Amlodipine 10mg Tablet

Diltiazem Hydrochloride

Formulary

Diltiazem Hydrochloride 60mg Tablet - FIRST LINE. For administration three times a day. No requirement for brand name prescribing.

Modified- release formulations should be prescribed by brand name.

Drug discontinuations
Slozem® 120mg, 180mg, 240mg and 300mg capsules* –discontinued from December 2019 (stock should run out by end of Feb 2020).

Felodipine

Formulary

Felodipine 2.5mg M/R Tablet
Felodipine 5mg M/R Tablet
Felodipine 10mg M/R Tablet

Nifedipine

Formulary

Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of nifedipine, prescribers should specify the brand to be dispensed.

Modified-release formulations may not be suitable for dose titration in hepatic disease. As per BNF

Drug discontinuations
Adalat 5mg immediate release capsules* –discontinued from February 2019.
Adalat 10mg immediate release capsules* – discontinued after March 2019
Adalat Retard 10mg modified release tablets – discontinued after November 2018
Adalat Retard 20mg modified release tablets – discontinued August 2018
Adalat LA 20mg*, 30mg and 60mg prolonged release – discontinued

*Bayer is the main supplier of these products.

See UKMI memo below on treatment alternatives.

UKMI: Adalat (nifedipine) products discontinuations and shortages

Nimodipine (Nimotop^®)

Formulary

Nimodipine 30mg Tablet

Restriction: For subarachnoid haemorrhage

Verapamil Hydrochloride

Formulary

Standard release tablets
Modified release formulations.

Securon SR tablets are cost-effective brands.

....

Key

	Notes
	Section Title (top level)
	Section Title (sub level)
	First Choice item
	Non Formulary section
	Restricted Drug
	Unlicensed
	Display tracking information
	Link to adult BNF
	Link to children's BNF
	Link to SPCs
	Scottish Medicines Consortium

	Cytotoxic Drug
	Controlled Drug
	High Cost Medicine
	Cancer Drugs Fund
	NHS England
	Homecare
	CCG
	High Cost Drug Approval System

Traffic Light Status Information

Status	Description
	Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available
	Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.
	Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary
	Medicines which can be prescribed in either Primary or Secondary Care.
	These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.